Degarelix

Generic Name: Degarelix

Brand Names: Firmagon, Degarelix Accord

Drug Type: Small Molecule

Chemical Formula: C_₈₂H_₁₀₃ClN_₁₈O_₁₆

CAS Number: 214766-78-6

Unique Ingredient Identifier: SX0XJI3A11

Background: Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.

Indication: Degaralix is used for the management of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Clinical Trials

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Drug: Bicalutamide
Drug: Abiraterone Acetate
Drug: Degarelix
Drug: Flutamide
Drug: Goserelin Acetate
Drug: Leuprolide Acetate
Drug: Nilutamide
Drug: Prednisone

First Posted Date: 2013-02-07

Last Posted Date: 2025-02-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 310

Registration Number: NCT01786265

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate plus degarelix
Drug: Abiraterone acetate
Drug: Degarelix

First Posted Date: 2012-12-18

Last Posted Date: 2021-11-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 124

Registration Number: NCT01751451

Locations: 🇺🇸
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸
NorthShore University Health System, Long Island City, New York, United States

and more 13 locations

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma
Non-Hodgkin's Lymphoma
Leukemia
Myelodysplastic Syndrome

Interventions: Biological: Palifermin
Biological: Lupron
Procedure: peripheral blood stem cell transplantation
Radiation: Total-Body Irradiation (TBI)
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Degarelix

First Posted Date: 2012-12-11

Last Posted Date: 2025-01-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 82

Registration Number: NCT01746849

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix
Drug: Goserelin

First Posted Date: 2012-12-06

Last Posted Date: 2015-06-23

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 285

Registration Number: NCT01744366

Locations: 🇨🇳
Affiliated Southwest Hospital of 3rd Military Medical University of People's Liberation Army, Chongqing, Chongqing, China
🇨🇳
2nd.Affiliated Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, Shanxi, China
🇨🇳
Cancer Institute & Hospital. Chinese Academy of Medical Sciences, Beijing, Beijing, China

and more 26 locations